

**PATENT** 

DL

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (MBHB Case No. 02-262)

In re Application of:		(ECENA		
	Sham-Yuen Chan	) )	NAN 2 8 2003	
Serial No.:	09/441,654	) Group Art Unit: 1653 (1765)	NTER 1600/2900	
Filed:	November 12, 1999	) Examiner: G. Bugaisky	1000/2900	
For:	Method of Producing Glycosylated Bikunin	) )		
Assistant C	Commissioner for Patents	,		

## TRANSMITTAL LETTER

Dear Sir:

Washington, D.C. 20231

In regard to the above-identified patent application:

- 1. We are transmitting herewith the attached:
  - a. Transmittal Letter, in duplicate;
  - b. Response to Office Action, mailed October 23, 2003; and
  - c. Return Receipt Postcard.
- 2. With respect to additional fees:

<u>X</u>	A.	No additional fee is required.
	B.	Attached is a check in the amount of \$

- 3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.10: The undersigned hereby certifies that this Transmittal Letter and the document(s) as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 22nd day of January, 2002.

EXPRESS MAIL NO.: EV 214232773 US

Date: January 22, 2003


By: Aaron F. Barkoff

Reg. No. P52,591



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 02-262)



Examiner: Bugaisky, Gabriele E.

Art Unit: 1653

Confirmation No.: 4743

JAN 2 8 2003

JECH CENTER 1600/2000

RESPONSE TO THE OFFICE ACTION MAILED OCTOBER 23, 2002

Commissioner for Patents Washington, D.C. 20231

Sir:

In Response to the Office Action mailed October 23, 2002, the applicants request that the Patent Office consider the following amendments and remarks.

## **Amendments**

## In the Specification:

On page 2, please replace the first paragraph with the following paragraph:

Placental bikunin, a novel human serine protease inhibitor containing two Kunitz-like domains, has been cloned and expressed (Delaria et al., J. Biol. Chem. 272(18): 12209-12214, 1997). Characterization studies showed that truncated placental bikunin is a potent inhibitor of kallikrein and plasmin. The sequence of truncated placental bikunin is shown in Figure 2. The protease inhibitory function of bikunin suggests that placental bikunin has important therapeutic application for the treatment of a variety of disorders including prevention of disseminated